Intrarectal povidone-iodine to reduce the risk of genitourinary infections after transrectal prostate biopsy
Main Article Content
Keywords
Biopsy, Prostate, Urinary tract, Povidone-Iodine
Abstract
Background: The aim of this study is to compare two different preparations in patients undergoing transrectal prostate biopsies samples (TPBS) and assess the prevalence of genitourinary infections (GUI).
Methods: A historical cohort of patients undergoing TBPS for suspected prostate cancer. Two groups were compared: one with endorectal lubricant jelly and another with the addition of a povidone-iodine lubricating jelly. Complications were evaluated at three weeks. A bivariate analysis was performed by calculating the OR (95 % CI) to determine if the additional endorectal povidone-iodine pre-TBPS reduced GUI and other complications.
Results: 185 patients (Group I n = 86, Group II n = 96) were evaluated. 45 and 25 % had genitourinary tract infection (OR: 0.4, CI: 0.2-0.9, p = 0.004); fever was presented in 21 and 10 % respectively (OR: 0.42, CI: 0.1-0.9, p = 0.04).
Conclusions: A reduction was observed in the presence of genitourinary infections in patients who had intrarectal povidone-iodine preparation applied.
References
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
Herranz-Amo F, Díez-Cordero JM, Cabello-Benavente R. Evolución de la Técnica de Biopsia Transrectal Ecodirigida de la Próstata. Arch. Esp. Urol. 2006; 59 (4):385-396.
Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159(2):471-5.
Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al.: Safety and morbidity of first andrepeat transrectal ultrasound guided prostate needle biopsies: Results of a Prospective European Prostate Cancer Detection Study. J Urol. 2001;166 (2):856-60.
Pepe P, Aragona F.: Morbidity after transperineal prostate biopsy in 3000 patients Undergoing 12 vs 18 vs more than 24 needle cores. J. Urol.2013;81(6):1142-6.
Collins GN, Lloyd SN, Hehir M. McKelvie GB: Multiple transrectal ultrasound guided prostatic biopsies—true morbidity and patient acceptance. Br J Urol.1993;71(4):460-3.
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy Data from Seer-Medicare. J Urol. 2001;186(5):1830-1834.
Zayotoun OM, Anil T, Moussa AS, Jianabo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 2011;77(4):910-4.
Carey JM, Korman HJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically sifnificant complications?. J Urol.2001;166(1):82-85.
Abughosh Z, Margolick J, Goldenberg SL, Taylor SA, Afshar K, Bell R et al.: A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol 2013;189(5):1326-31.
Gil-Vernet Sedo JM, Alvarez-Vijande García R. Effect of intrarectal povidone-iodine in the incidence of infectious complications after transrectal prostatic biopsy. Arch. Esp. Urol.2012;65(4):463-466.
Ghafoori M, Shakiba M, Seifmanesh H, Hoseini K. Decrease in infection rate following use of povidone-iodine during transrectal ultrasound guided biopsy of the prostate: a double blind randomized clinical trial. Iran J Radiol. 2012; 9(2):67-70.
Kanjanawongdeengam P, Viseshsindh W, Santanirand P, PrathombutrP, Nilkulwattana S. Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial. J Med Assoc Thai.2009;92(12):1621-6.
Rees M. Povidone-iodine antisepsis for transrectal prostatic biopsy. Br Med J. 1980;281(6241):650.
Lachapelle JM, Castel O, Fueyo Casado A, Leroy B, Micali G, Tennstedt D, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract. 2013;10(5):579-592.
Pu Ch, Bai Y, Yuan H, Li J, Tang Y, Huang J et al. Reducing the risk of infections for transrectal prostate biopsy with povidone-iodine: a systematic review and meta-analysis. Int Urol Nephrol 2014;46:1691-1698.
Park DS, Oh JJ, Lee JH, Jang Wk, Hong YK, Hong SK. Simple use of the suppository type povidone-iodinecan prevent infectious complications in transrectal ultrasound-guided prostate biopsy. Adv Urol2009; Article ID 750598, 4 pages. Doi:10.1155/2009/750598.
Liss MA, Nakamura KK, Meuleners R, Kolla SB, Dash A, Pterson EM. Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?. Urology.2013;82(1):67-71
Batura D, Rao GG, Nielsen PB. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int;2010;107(7):1017-20.
Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013;189:S12-S18.
Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Flouroquinolone-resistant E. Coli in intestinal flora of patients undergoing transrectal ultrasound guided prostate biopsy—should we reassess our practices for antibiotic prophylaxis?. Clin Microbiol Infect 2012;18:575-581.
Liss MA, Chang A, Santos R, Nakama-Peeples A, Peterson EM, Osannn K, et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients underogoing transrectal ultrasound guided prostate needle biopsy. J Urol.2001;185(4)1283-8.
Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. Emergence of fluorquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: Implications for prophylaxis and treatment. Urology 2011; 77 (5): 1035-41.